Related Experiment Video
Updated: Jul 5, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
New perspectives for better R&D performance: lessons learned from leading pharma companies
Alexander Schuhmacher1, Oliver Gassmann2, Sara Knapp2
1Technische Hochschule Ingolstadt, Germany; University of St Gallen, St Gallen, Switzerland.
None:
The research and development (R&D) productivity of pharmaceutical companies has been widely studied and analyzed for many years in both academia and industry, and pharmaceutical companies have launched various initiatives to improve their R&D efficiency, such as by opening R&D toward external innovation, improved decision-making, or better clinical trial management. However, these efforts are based primarily on an inward-looking organizational perspective and have so far not benchmarked new drugs invented internally and those acquired from external sources. Here, we analyze new drugs approved between 2011 and 2022 developed by the top 20 pharmaceutical companies, differentiating between internal and external innovation, with a particular focus on internally invented new drugs. Based on our analysis, we provide deep insights into the R&D strategies of the leading companies and draw conclusions about how companies could further improve their R&D performance.
Related Concept Videos
Drug Discovery: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacogenomics: Identification of New Drug Targets
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

